



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated April 12, 2024

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: US FDA audit for Granules India's Unit V facility results in Zero 483s

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Mam,

Please be informed that the Company's Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India underwent a US FDA inspection from 8th April 2024 to 12th April 2024. This audit was a Pre Approval Inspection (PAI) and cGMP audit for Active Pharmaceutical Ingredients (APIs) and Formulations (FDs); oncology and non-oncology. The audit resulted in Zero 483's.

This facility manufactures APIs & formulations of oncology and non-oncology products.

This is for your information and dissemination to the members of the exchange.

Thanking You.

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**